Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant for CINV in Pediatric Patients
NCT02519842Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by Merck & Co.. Started Sep 2015; status: terminated.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT02519842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02519842.